LENZ Therapeutics demonstrated robust performance during the initial phase of the VIZZ launch in the first quarter.
The company filled over 20,000 prescriptions, resulting in approximately $1.6 million in net product revenue.
More than 6,500 eye care professionals prescribed VIZZ, with a significant percentage prescribing multiple times.
Commercial Success
LENZ Therapeutics achieved significant commercial milestones, generating $1.6 million in net product revenue through 20,000 filled prescriptions in Q4 2025.
Healthcare Professional Engagement
Over 6,500 eye care professionals engaged with VIZZ, indicating strong acceptance with over 55% repeating prescriptions, reflecting high product efficacy.
Global Expansion
The partnership with Lunatus in the Middle East positions LENZ for international growth, marking a strategic step towards diversifying revenue streams in new markets.
- The swift uptake of VIZZ in Q4 2025 underscores strong market demand and confidence in the product among healthcare professionals.
- The collaboration with Lunatus in the Middle East signifies LENZ's strategic vision to expand globally, tapping into new markets for sustained growth and revenue diversification.
LENZ Therapeutics' outstanding performance in Q4 2025, coupled with strategic partnerships like the one with Lunatus, underscores the company's growth potential and competitive positioning in the pharmaceutical sector.